Young Biopharma, LLC

Andover, MA · Biotech · Private

Novel small-molecule compound (YB-...) derived from capsaicin with TRPV1 modulatory activity for topical pain relief

youngbiopharma.com →
Grants
$225K
1 award
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
3
0 granted · 3 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · A novel TRP modulator YB-2 to fight opioid crisis and treat chronic pain$225,000
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1259AYTU BIOSCIENCE, INC—$26M
1260NANODESK, LLC——
1261CODOMAX INC.——
1262Young Biopharma, LLC——
1263Proteovant Therapeutics——
1264Pelthos Therapeutics Inc.—$69M
1265Mediar Therapeutics—$75M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 0 granted of 3
  • Novel Capsaicin Analogs And Uses Thereofapplication
  • Novel Capsaicin Analogs And Uses Thereofapplication
  • Novel Capsaicin Analogs and Uses Thereforapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.